Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma

Completed · Phase 2

Conditions studied: CNS Cancer, CNS BRAIN

In brief

The purpose of this study is to see how effective treatment of high doses of chemotherapy is for your tumor. We will also be looking at the side effects and risks of this treatment. You will receive very high doses of chemotherapy. High doses of chemotherapy can destroy tumor cells, but it can also destroy normal bone marrow cells. These cells produce white blood cells (which fight infection), red blood cells (which carry oxygen) and platelets (which allow your blood to clot). With too few of these cells there is a serious risk of infection and bleeding. Therefore, before treatment begins, we will collect some of your own blood cells, called peripheral blood progenitor cells (PBPCs). These cells help create new blood cells. The PBPCs are frozen and saved while you are being treated. Then at the end of treatment, your PBPCs are thawed and given back to you. These healthy PBPCs will replace the blood cells that the high dose chemotherapy destroys and allow your bone marrow to recover and produce blood cells. In a prior study we treated 69 patients in a similar way. More than half were able to avoid or delay brain radiation. This new study will use a different high dose chemotherapy regimen.

Key facts

Study ID

NCT00588523

Run by

Memorial Sloan Kettering Cancer Center

People needed

60

Starts

2002-09-01

Expected to finish

2023-02-02

Last updated by the study team

2023-10-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologic evidence of an anaplastic oligodendroglioma. For this study, World Health Organization classification criteria will be used. Central pathology review must take place prior to high-dose therapy but need not occur prior to study entry and induction therapy.
• Pathologic evidence of an anaplastic mixed glioma (i.e. oligoastrocytoma). Again, histopathologic diagnosis will be made using World Health Organization classification criteria. To qualify as a mixed tumor there must be a minimum of 25% oligodendroglial element. Central pathology review must take place prior to high-dose therapy but need not occur in advance of enrollment or induction therapy.
• The diagnostic surgical procedure may have been a complete resection, partial resection, or biopsy.
• Karnofsky performance status > or equal to 60.
• Granulocyte count > or equal to 1.5 X 109/L.
• Platelet count > or equal to 100 X 109/L
• SGOT < than or equal to 2X upper limit of normal.
• Serum creatinine < than or equal to 1.5X upper limit of normal
• Bilirubin < than or equal to 1.5X upper limit of normal
• All patients must sign written informed consent.

You may not qualify if…

• Systemic or leptomeningeal metastases (excluding contiguous leptomeninges)
• Prior cranial radiotherapy or systemic chemotherapy
• Other concurrent malignancy (with the exception of cervical carcinoma in situ or basal cell carcinoma of the skin) or serious illness if this would interfere with the prescribed treatment.
• Pregnant or lactating women
• Refusal to use effective contraception

Where it is running

• Memorial Sloan Kettering Cancer Center — Basking Ridge, New Jersey, United States
• Memorial Sloan Kettering Cancer Center — Commack, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.